EU research on Ebola
Five projects are being funded, including a trial of the most advanced vaccine against Ebola being developed by GSK (with an EU financial contribution €15.1 million). This vaccine is already being tested in humans, with very promising results being seen so far. Other projects are studying the potential therapeutic effect on Ebola patients of an existing treatment against influenza (favipiravir), plasma from survivors, and serum from antibody-producing horses. A further project is working on the transmission of the virus and the clinical importance of its mutations.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s